Candriam SCA
BBIO icon

Candriam SCA’s BridgeBio Pharma BBIO Stock Holding History

Candriam SCA’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$46.4M Buy
702,845
+402,325
+134% +$31.3M 0.21% 98
2026
Q2 		$22.4M Buy
300,520
+21,632
+8% +$1.52M 0.1% 190
2026
Q1 		$20.7M Hold
278,888
– – 0.11% 190
2025
Q4 		$21.3M Buy
278,888
+129,902
+87% +$8.53M 0.11% 182
2025
Q3 		$7.74M Buy
+148,986
New +$7.27M 0.04% 304
2024
Q2 		– Sell
-380,000
Closed -$11.7M – 693
2024
Q1 		$11.7M Buy
380,000
+81,000
+27% +$2.75M 0.08% 240
2023
Q4 		$12.1M Buy
299,000
+54,000
+22% +$1.62M 0.08% 231
2023
Q3 		$6.46M Sell
245,000
-40,000
-14% -$1.14M 0.05% 284
2023
Q2 		$4.9M Hold
285,000
– – 0.04% 335
2023
Q1 		$4.35M Buy
285,000
+188,756
+196% +$2.2M 0.03% 396
2022
Q4 		$733K Buy
96,244
+469
+0.5% +$4.49K ﹤0.01% 758
2022
Q3 		$952K Sell
95,775
-306,137
-76% -$3.18M 0.01% 717
2022
Q2 		$3.65M Hold
401,912
– – 0.03% 376
2022
Q1 		$4.08M Hold
401,912
– – 0.03% 392
2021
Q4 		$6.7M Sell
401,912
-53,373
-12% -$2.26M 0.04% 306
2021
Q3 		$21.3M Hold
455,285
– – 0.15% 166
2021
Q2 		$27.8M Buy
+455,285
New +$26M 0.19% 124

Other funds holding BBIO

Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.04B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Candriam SCA's BBIO Position: Q3 2026 in Review

Candriam SCA increased its BridgeBio Pharma (BBIO) stake by 134% in Q3 2026, buying an estimated $31.3M and bringing the position to 702,845 shares worth $46.4M. The position accounts for 0.21% of the portfolio, ranked #98.

Candriam SCA first reported a position in BBIO in Q2 2021 and has held it in 17 quarters since. 330 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Candriam SCA held 702,845 shares of BridgeBio Pharma worth $46.4M as of Q3 2026.
  • Candriam SCA bought 402,325 BridgeBio Pharma shares in Q3 2026, an estimated $31.3M.
  • BridgeBio Pharma made up 0.21% of Candriam SCA's portfolio in Q3 2026, its #98 holding.
  • Candriam SCA first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 17 quarters since.
  • 330 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.